SI1603584T1 - Aplidin za zdravljenje multiple mieloma - Google Patents

Aplidin za zdravljenje multiple mieloma

Info

Publication number
SI1603584T1
SI1603584T1 SI200430878T SI200430878T SI1603584T1 SI 1603584 T1 SI1603584 T1 SI 1603584T1 SI 200430878 T SI200430878 T SI 200430878T SI 200430878 T SI200430878 T SI 200430878T SI 1603584 T1 SI1603584 T1 SI 1603584T1
Authority
SI
Slovenia
Prior art keywords
aplidine
multiple myeloma
myeloma treatment
treatment
medicament
Prior art date
Application number
SI200430878T
Other languages
English (en)
Inventor
Joseph R Bertino
Daniel Medina
Glynn Thomas Faircloth
Constantine S Mitsiades
Kenneth Anderson
Nicholas Mitsiades
Original Assignee
Dana Farber Cancer Inst Inc
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Pharma Mar Sa filed Critical Dana Farber Cancer Inst Inc
Publication of SI1603584T1 publication Critical patent/SI1603584T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200430878T 2003-03-12 2004-03-12 Aplidin za zdravljenje multiple mieloma SI1603584T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
US52029303P 2003-11-14 2003-11-14
EP04720081A EP1603584B1 (en) 2003-03-12 2004-03-12 Aplidine for multiple myeloma treatment
PCT/GB2004/001062 WO2004080477A1 (en) 2003-03-12 2004-03-12 Aplidine for multiple myeloma treatment

Publications (1)

Publication Number Publication Date
SI1603584T1 true SI1603584T1 (sl) 2009-02-28

Family

ID=32994545

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430878T SI1603584T1 (sl) 2003-03-12 2004-03-12 Aplidin za zdravljenje multiple mieloma

Country Status (20)

Country Link
US (1) US7381703B2 (sl)
EP (1) EP1603584B1 (sl)
JP (1) JP4584245B2 (sl)
KR (1) KR101160320B1 (sl)
AT (1) ATE406171T1 (sl)
AU (1) AU2004218883B2 (sl)
CA (1) CA2519789C (sl)
CY (1) CY1108599T1 (sl)
DE (1) DE602004016126D1 (sl)
DK (1) DK1603584T3 (sl)
ES (1) ES2312979T3 (sl)
IL (1) IL170136A (sl)
MX (1) MXPA05009742A (sl)
NO (1) NO334264B1 (sl)
NZ (1) NZ541611A (sl)
PL (1) PL1603584T3 (sl)
PT (1) PT1603584E (sl)
RU (1) RU2335294C2 (sl)
SI (1) SI1603584T1 (sl)
WO (1) WO2004080477A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518847A (en) * 1999-11-15 2004-02-27 Pharma Mar S Aplidine treatment of cancers
EP1620117A4 (en) 2003-03-12 2009-07-29 Pharma Mar Sa IMPROVED ANTITUMORAL TREATMENTS
EP1942944A2 (en) * 2005-10-31 2008-07-16 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
EP2029155B1 (en) 2006-02-28 2016-04-13 Pharma Mar S.A. Improved treatment of multiple myeloma
WO2008080956A1 (en) * 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
US20110123486A1 (en) * 2007-06-25 2011-05-26 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
EP2205263A1 (en) * 2007-10-19 2010-07-14 Pharma Mar, S.A. Improved antitumoral treatments
MX2010009697A (es) * 2008-03-07 2010-09-30 Pharm Mar S A Tratamientos anticancerigenos mejorados.
WO2009138509A1 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Multiple myeloma treatments
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
EP0048149B1 (en) 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
AU681231B2 (en) * 1993-12-29 1997-08-21 Intarcia Therapeutics, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
NZ333428A (en) 1996-07-03 2000-09-29 Mckechnie United Kingdom Ltd Stacking and nesting containers with formations on tops of side walls to enhance stability when containers placed side by side
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
CA2288639A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
PT1100589E (pt) * 1998-07-30 2005-05-31 Sigma Tau Ind Farmaceuti Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003500360A (ja) 1999-05-25 2003-01-07 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物類を含む抗癌剤
NZ518847A (en) 1999-11-15 2004-02-27 Pharma Mar S Aplidine treatment of cancers
IL152111A0 (en) 2000-04-07 2003-07-31 Univ Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU2002213053B2 (en) * 2000-10-05 2006-12-21 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
CA2424823A1 (en) * 2000-10-12 2002-04-18 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
EP1620117A4 (en) 2003-03-12 2009-07-29 Pharma Mar Sa IMPROVED ANTITUMORAL TREATMENTS

Also Published As

Publication number Publication date
CY1108599T1 (el) 2014-04-09
DE602004016126D1 (de) 2008-10-09
KR20060006779A (ko) 2006-01-19
US7381703B2 (en) 2008-06-03
WO2004080477A1 (en) 2004-09-23
WO2004080477A8 (en) 2004-11-11
EP1603584A1 (en) 2005-12-14
PT1603584E (pt) 2008-11-21
EP1603584B1 (en) 2008-08-27
RU2335294C2 (ru) 2008-10-10
DK1603584T3 (da) 2009-01-05
JP4584245B2 (ja) 2010-11-17
CA2519789C (en) 2012-07-03
NZ541611A (en) 2008-04-30
ATE406171T1 (de) 2008-09-15
AU2004218883A1 (en) 2004-09-23
RU2005131578A (ru) 2006-01-27
IL170136A (en) 2014-04-30
CA2519789A1 (en) 2004-09-23
AU2004218883B2 (en) 2009-10-01
NO334264B1 (no) 2014-01-20
JP2006519828A (ja) 2006-08-31
ES2312979T3 (es) 2009-03-01
NO20054668L (no) 2005-10-11
US20070149445A9 (en) 2007-06-28
MXPA05009742A (es) 2006-05-25
PL1603584T3 (pl) 2009-02-27
US20060172926A1 (en) 2006-08-03
KR101160320B1 (ko) 2012-06-26

Similar Documents

Publication Publication Date Title
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
MY138285A (en) Fab i inhibitors
GB0201674D0 (en) Medical treatment
HK1078784A1 (en) Therapeutic treatment
UA88655C2 (ru) S-миртазапин для лечения прилива крови
MY141007A (en) Use of an alpha-2-delta ligand for the treatment of luts
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
MY135829A (en) Analeptic and drug combinations
GB0223367D0 (en) Therapeutic treatment
GB0218879D0 (en) Medical treatment
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
WO2004080421A3 (en) Improved antitumoral treatments
MXPA05011830A (es) Peptidos para uso en el tratamiento de la obesidad.
IL175579A0 (en) Epithelium treatment methods and devices for treating the epithelium
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
GB0210464D0 (en) Therapeutic treatment
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
RS52038B (en) USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS
GB0327493D0 (en) Treatment medicament
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
AU2003265321A8 (en) Treatments and methods for the treatment, diagnosis and prophylaxis
AU2003209489A1 (en) Medical use of captopril for the treatment and prophylaxis of cancer